Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 6/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499085 | 0.80 | THRB (0.43) | THRBTHRANR5A1PLA2G2AGGPS1 | |
| SCHEMBL17052949 | 0.80 | SLC22A12 (0.42) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6487877 | 0.77 | NPC1 (0.39) | THRBTHRANR5A1PLA2G2AGGPS1 | |
| SCHEMBL27291555 | 0.75 | NPC1 (0.47) | NPC1RAB9AHSD17B10SMN1; SMN2LMNA | |
| SCHEMBL6489323 | 0.73 | GABRA1 (0.49) | THRBTHRAPLA2G2ANPC1RAB9A | |
| SCHEMBL9650394 | 0.72 | THRB (0.52) | THRBTHRANR5A1LTA4HTP53 | |
| SCHEMBL8876537 | 0.72 | NPC1 (0.52) | THRBTHRANR5A1NPC1RAB9A | |
| SCHEMBL8875097 | 0.72 | NR5A1 (0.55) | THRBTHRANR5A1NPC1RAB9A | |
| SCHEMBL17160967 | 0.71 | SLC22A12 (0.39) | NPC1RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL8123046 | 0.71 | NR5A1 (0.48) | THRBNR5A1PLA2G2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | THRB 2919/4885THRA 3559/4885NR5A1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.